Inception- 2015

Location- Gurugram

Industry domain- Molecular diagnostics

Founders & Investors- Sushil Mehta (Chairman), Varun Chopra (Director), Dr Pravin Kini, Srinivas Aluri Rao, TV Rajan, Ameet Desai and Ashok Jain

Total team strength- 30 (R&D- 10, commercial/sales- 10, support- 10)

Total funds raised- Rs 18.5 crore invested, received grants from Biotechnology Industry Research Assistance Council (BIRAC) and the United States - India Science and Technology Endowment Fund (USISTEF)

Revenue generated since inception- Rs 73 crore

Key Highlights-

• Launched TB-Lamp solution in partnership with Germany-based Human Diagnostics for faster diagnosis of TB
• Had seven or eight installations of TB-Lamp solution across hospitals and clinics
• Got approval for multiplex RT-PCR test named COVSCAN qPCR-96 and an antigen test
• Developed serology-based TB test; under trial
• To raise funds for manufacturing facility and expansion of R&D

Founder Speaks-

"About 4.8 lakh people lose their life to TB in India every year. The statistics are especially alarming because TB can be cured if diagnosed and treated in time. Studies have shown that older methods like smear microscopy are not sensitive enough and result in a lot of false negatives-they are only right in 50% of the cases which means that 1 in 2 cases are left undiagnosed. Our pioneering technology of TB LAMP tackles this problem with its innovative DNA extraction that results in high specificity and sensitivity and low turnaround times. In the future, we see our diagnostic technologies adopted all over India, even in remote and underserved places. The Government of India has a vision of making the country Tuberculosis free by 2025, and only with greater public, private, and academia collaboration can we hope to achieve this goal."

- Sushil Mehta, Chairman, NextGen Invitro Diagnostics, Gurugram